| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
PR Newswire, San Diego, June 3, 2019 – Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion of the ongoing Phase 1b/2 clinical trial...
PR Newswire, San Diego, May 15, 2019 – – Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical...
PR Newswire, San Diego, April 16, 2019 – Viracta Therapeutics, Inc. announced today that the U. S. Food & Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to their Phase 2...
San Diego, CA and Shenzhen, China, December 4, 2018 - Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a...
San Diego, CA, September 25, 2018 - Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious...
